Zura Bio Ltd

Zura Bio Ltd (Nasdaq: ZURA) is a clinical-stage biopharmaceutical company focused on inflammatory and autoimmune diseases that entered public markets in 2023 through a business combination with JAWS Healthcare Innovators Acquisition Corp, a healthcare-sector blank-check vehicle that completed its initial public offering in 2021. The SPAC was sponsored by JAWS Healthcare Innovators Sponsor LLC. Zura Bio filed an S-1 registration statement with the Securities and Exchange Commission in May 2024, accession number 0001410578-24-000964, covering shares issued in connection with the de-SPAC transaction. The company operates in the life sciences and biotechnology sector and remains publicly listed. For comprehensive filing histories, sponsor profiles, and deal analytics across the SPAC market, sign up for full data access at SpacDesk.